- Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Entrada Therapeutics Reports First Quarter 2024 Financial Results
- Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics Promotes Nathan J. Dowden to President
- Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
- Entrada Therapeutics Reports Third Quarter 2023 Financial Results
- Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
- Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
- Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
More ▼
Key statistics
On Friday, Entrada Therapeutics Inc (TRDA:NMQ) closed at 14.99, -18.71% below its 52-week high of 18.44, set on Jul 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.34 |
---|---|
High | 15.34 |
Low | 14.78 |
Bid | 14.43 |
Offer | 23.88 |
Previous close | 14.95 |
Average volume | 68.07k |
---|---|
Shares outstanding | 33.76m |
Free float | 28.17m |
P/E (TTM) | 23.90 |
Market cap | 506.05m USD |
EPS (TTM) | 0.6273 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼